Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer
Further Publications Urology
Related content
Uro-Oncology
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921
J Clin Oncol.
Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W1, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM
doi: 10.1200/JCO.2017.76.4126.
Uro-Oncology
Comparative Effectiveness of Radical Prostatectomy With Adjuvant Radiotherapy Versus Radiotherapy Plus Androgen Deprivation Therapy for Men With Advanced Prostate Cancer
Cancer.
Jang TL, Patel N, Faiena I, Radadia KD, Moore DF, Elsamra SE, Singer EA, Stein MN, Eastham JA, Scardino PT, Lin Y, Kim IY, Lu-Yao GL
doi: 10.1002/cncr.31726.
Further Publications Urology
Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials
Prostate Cancer Prostatic Dis
Jiang T, Markovic D, Patel J, Juarez JE, Ma TM, Shabsovich D, Nickols NG, Reiter RE, Elashoff D, Rettig MB, Zaorsky NG, Spratt DE, Kishan AU
doi: 10.1038/s41391-021-00432-2
COMMENTED
Uro-Oncology
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.033.
Uro-Oncology
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial
Eur Urol.
Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Fransson AS, Leskinent MJ, Zeke M, Huttunen T, Ginman C, Investigators of the Scandinavian Prostate Cancer Study No. 13.
doi: 10.1016/j.eururo.2019.08.010.
Uro-Oncology
Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series
Eur Urol.
Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N4, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A
doi: 10.1016/j.eururo.2017.11.020.
Uro-Oncology
Risk of dementia following androgen deprivation therapy for treatment of prostate cancer
Prostate Cancer Prostatic Dis.
Krasnova A, Epstein M, Marchese M, Dickerman BA, Cole AP, Lipsitz SR, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, Mucci LA, Sun M, Trinh QD
doi: 10.1038/s41391-019-0189-3.
Uro-Oncology
Systemic treatments for high-risk localized prostate cancer
Nat Rev Urol.
Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D
doi: 10.1038/s41585-018-0017-x.
Further Publications UrologyFurther Publications Gynecology
A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance
Prostate.
Jarrard D, Filon M, Huang W, Havighurst T, DeShong K, Kim K, Konety BR, Saltzstein D, Mukhtar H, Wollmer B, Suen C, House MG, Parnes HL, Bailey HH
doi: 10.1002/pros.24076.